343 related articles for article (PubMed ID: 32818545)
21. Perspectives for repurposing drugs for the coronavirus disease 2019.
Cherian SS; Agrawal M; Basu A; Abraham P; Gangakhedkar RR; Bhargava B
Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):160-171. PubMed ID: 32317408
[TBL] [Abstract][Full Text] [Related]
22. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.
Unni S; Aouti S; Thiyagarajan S; Padmanabhan B
J Biosci; 2020; 45(1):. PubMed ID: 33184246
[TBL] [Abstract][Full Text] [Related]
23. Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.
Chakraborti S; Bheemireddy S; Srinivasan N
Mol Omics; 2020 Oct; 16(5):474-491. PubMed ID: 32696772
[TBL] [Abstract][Full Text] [Related]
24. An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors.
Trezza A; Iovinelli D; Santucci A; Prischi F; Spiga O
Sci Rep; 2020 Aug; 10(1):13866. PubMed ID: 32807895
[TBL] [Abstract][Full Text] [Related]
25. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
Park SJ; Yu KM; Kim YI; Kim SM; Kim EH; Kim SG; Kim EJ; Casel MAB; Rollon R; Jang SG; Lee MH; Chang JH; Song MS; Jeong HW; Choi Y; Chen W; Shin WJ; Jung JU; Choi YK
mBio; 2020 May; 11(3):. PubMed ID: 32444382
[TBL] [Abstract][Full Text] [Related]
26. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.
Xu J; Shi PY; Li H; Zhou J
ACS Infect Dis; 2020 May; 6(5):909-915. PubMed ID: 32125140
[TBL] [Abstract][Full Text] [Related]
27. Tackling SARS-CoV-2: proposed targets and repurposed drugs.
Joshi S; Joshi M; Degani MS
Future Med Chem; 2020 Sep; 12(17):1579-1601. PubMed ID: 32564623
[TBL] [Abstract][Full Text] [Related]
28. Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point.
Rogosnitzky M; Berkowitz E; Jadad AR
JMIR Public Health Surveill; 2020 May; 6(2):e19199. PubMed ID: 32374264
[TBL] [Abstract][Full Text] [Related]
29. Drug repositioning is an alternative for the treatment of coronavirus COVID-19.
Serafin MB; Bottega A; Foletto VS; da Rosa TF; Hörner A; Hörner R
Int J Antimicrob Agents; 2020 Jun; 55(6):105969. PubMed ID: 32278811
[TBL] [Abstract][Full Text] [Related]
30. Fight against novel coronavirus: A perspective of medicinal chemists.
Amin SA; Jha T
Eur J Med Chem; 2020 Sep; 201():112559. PubMed ID: 32563814
[TBL] [Abstract][Full Text] [Related]
31. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach.
Parvez MSA; Karim MA; Hasan M; Jaman J; Karim Z; Tahsin T; Hasan MN; Hosen MJ
Int J Biol Macromol; 2020 Nov; 163():1787-1797. PubMed ID: 32950529
[TBL] [Abstract][Full Text] [Related]
32. Emerging strategies on in silico drug development against COVID-19: challenges and opportunities.
Yadav M; Dhagat S; Eswari JS
Eur J Pharm Sci; 2020 Dec; 155():105522. PubMed ID: 32827661
[TBL] [Abstract][Full Text] [Related]
33. Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines.
Vitte J; Michel M; Mezouar S; Diallo AB; Boumaza A; Mege JL; Desnues B
Front Immunol; 2020; 11():2159. PubMed ID: 32983179
[TBL] [Abstract][Full Text] [Related]
34. Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs.
Skariyachan S; Gopal D; Chakrabarti S; Kempanna P; Uttarkar A; Muddebihalkar AG; Niranjan V
Comput Biol Med; 2020 Nov; 126():104054. PubMed ID: 33074111
[TBL] [Abstract][Full Text] [Related]
35. Repurposing Existing Drugs for the Treatment of COVID-19.
Farne H; Kumar K; Ritchie AI; Finney LJ; Johnston SL; Singanayagam A
Ann Am Thorac Soc; 2020 Oct; 17(10):1186-1194. PubMed ID: 32692580
[TBL] [Abstract][Full Text] [Related]
36. Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19.
Kumar S; Zhi K; Mukherji A; Gerth K
Viruses; 2020 Apr; 12(5):. PubMed ID: 32357553
[TBL] [Abstract][Full Text] [Related]
37. Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?
Severa M; Farina C; Salvetti M; Coccia EM
Front Immunol; 2020; 11():1459. PubMed ID: 32655578
[No Abstract] [Full Text] [Related]
38. Current Perspective of Antiviral Strategies against COVID-19.
Ahidjo BA; Loe MWC; Ng YL; Mok CK; Chu JJH
ACS Infect Dis; 2020 Jul; 6(7):1624-1634. PubMed ID: 32485102
[TBL] [Abstract][Full Text] [Related]
39. Application of Artificial Intelligence in COVID-19 drug repurposing.
Mohanty S; Harun Ai Rashid M; Mridul M; Mohanty C; Swayamsiddha S
Diabetes Metab Syndr; 2020; 14(5):1027-1031. PubMed ID: 32634717
[TBL] [Abstract][Full Text] [Related]
40. Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2.
Tripathi PK; Upadhyay S; Singh M; Raghavendhar S; Bhardwaj M; Sharma P; Patel AK
Int J Biol Macromol; 2020 Dec; 164():2622-2631. PubMed ID: 32853604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
